Neural Analytics Inc., a medical device company developing and commercializing technology to measure, diagnose and track brain health, today announced the latest system update for its next generation ultrasound device, the Lucid M1 Transcranial Doppler Ultrasound System™ (Lucid System). The Lucid System is an FDA cleared fully portable, all-in-one ultrasound system designed for measuring and displaying cerebral blood flow velocities and monitoring of patients with brain disorders.
“The launch of our latest system update further demonstrates our commitment to continually enhance our technology to better meet the needs of healthcare professionals and their patients,” said Leo Petrossian, Chief Executive Officer of Neural Analytics. “This launch has the potential to optimize patient care by enabling clinicians to quickly access critical brain health information with the option to save and archive data from our platform across the entire hospital network.”
The Lucid System uses a type of ultrasound called Trans Cranial Doppler to assess the brain’s blood vessels from outside the body. This analysis is non-invasive, can be performed in the physician’s office and can help the physician diagnose brain disorders, potentially eliminating the need for additional, more invasive tests. Many significant brain disorders are caused by blood flow disruption. The Lucid System is a battery operated medical grade tablet device designed to be moved easily throughout a medical facility in a range of settings that require the rapid assessment of blood flow in the brain to expedite treatment.